



DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

Date: January 18, 2023
Time: 10:00am – 3:00pm (CT)
Location: Howerton State Office Building
Conference Room 202
Jefferson City, MO 65109
OR WebEx

Additional Meeting Details
The meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2451 340 3184
Meeting password: DMcpxA9g9k2

Join from a Video System/Application
Dial 24528696537@stateofmo.webex.com
Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)
[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

| Opening Statements/Updates | | |
|---------------------------------|----------------------------------------------------------------------------------------------------|---------------------|
| 10:00 – 10:05 | Welcome, Announcements and Introductions | Chairperson |
| 10:05 – 10:15 | Minutes Review | Discussion/Approval |
| 10:15 – 10:25 | Pharmacy Program/Budget Update | Elizabeth Short |
| 10:25 – 10:40 | Prior Authorization Process and Update | Elizabeth Sissom |
| 10:40 – 10:50 | Review of Prior Authorization Meeting and Public Hearing | Josh Moore |
| Old Business | | |
| 10:50 – 11:00 | Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's | Josh Moore |
| New Business | | |
| 11:00 – 11:15 | Proposed Actions – New Drug/Product Review | Josh Moore |
| | i. Open Access | |
| | ii. Clinical Edit/Step Therapy | |
| | iii. Resource List | |
| | iv. PDL Agents | |
| | v. Prior Authorization | |
| Clinical and Fiscal Edit Review | | |
| 11:15 – 12:00 | <u>Existing Criteria</u> | Josh Moore |
| | i. Aduhelm Clinical Edit | |
| | ii. Antipsychotics, 1st Generation (Typical) Clinical Edit | |
| | iii. Benzodiazepine, Select Oral Clinical Edit | |
| | iv. Butalbital Combinations without Codeine Clinical Edit | |

- v. Corlanor Clinical Edit
- vi. Empaveli Clinical Edit
- vii. HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit
- viii. High Risk Therapies Clinical Edit
- ix. Kerendia Clinical Edit
- x. Morphine Milligram Equivalent (MME) Accumulation Clinical Edit
- xi. Non-Oral Contraceptives Fiscal Edit
- xii. Oxazolidinone Fiscal Edit
- xiii. Pompe Disease Clinical Edit
- xiv. Selzentry Clinical Edit
- xv. Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit
- xvi. Verquvo Clinical Edit

New Criteria or Revision of Existing Criteria

- i. Camzyos Clinical Edit
- ii. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit
- iii. Opioids, Short Acting Clinical Edit
- iv. Skysona Clinical Edit
- v. Xenpozyme Clinical Edit
- vi. Ztalmy Clinical Edit
- vii. Zynteglo Clinical Edit

Resource List Edit Review

12:00 – 12:30 Existing Criteria - none Josh Moore

New Criteria or Revision of Existing Criteria

- i. Antipsychotics - 2nd Generation (Atypical) Depot Agents
- ii. Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents

Break

12:30 – 12:45 Lunch

Preferred Drug List Edit Review

12:45 – 1:45 Existing Criteria Josh Moore

- i. Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists & Combinations PDL Edit
- ii. Antiemetics, 5-HT3 and NK1 Injectables PDL Edit
- iii. Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit
- iv. Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit
- v. Anti-Parkinsonism, MAO-B Inhibitors PDL Edit
- vi. Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit
- vii. Antiplatelet Agents PDL Edit
- viii. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit
- ix. Glucagon Agents PDL Edit
- x. Hereditary Angioedema Agents PDL Edit
- xi. NSAIDs PDL Edit
- xii. Opioid Emergency Reversal Agents PDL Edit
- xiii. Opioids, Long Acting PDL Edit
- xiv. Somatostatin Analogs PDL Edit
- xv. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit

New Criteria or Revision of Existing Criteria

- i. Antiandrogenic Agents PDL Edit

- ii. Anticonvulsants, Dravet Syndrome PDL Edit
- iii. Anti-Migraine, Alternative Oral Agents PDL Edit
- iv. Antiretroviral Therapy (ART) PDL Edit
- v. Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit
- vi. Fibromyalgia Agents PDL Edit
- vii. GI Motility Agents, Chronic PDL Edit
- viii. Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit
- ix. Neuropathic Pain Agents PDL Edit
- x. Opioid & Select Alcohol Dependence Agents PDL Edit
- xi. Sedative Hypnotics PDL Edit
- xii. Skeletal Muscle Relaxants PDL Edit
- xiii. Tramadol-Like Agents PDL Edit

Program Utilization Information

| | | |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------|
| 1:45 – 2:00 | Conduent Reports <ul style="list-style-type: none"> i. Call Center Statistics ii. “Top 25” Drugs by Cost/Claims | Jennifer Colozza |
| 2:00 – 2:15 | Conduent Retro DUR Report | Dimple Patel |

Other Business/Closing Comments

| | | |
|-------------|----------------|------------|
| 2:15 – 2:30 | Other Business | Josh Moore |
|-------------|----------------|------------|

Executive Session

| | | |
|-------------|---------------|------------|
| 2:30 – 3:00 | Data Analysis | Josh Moore |
|-------------|---------------|------------|

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

Next Meeting: April 20, 2023
Meeting location and attendance options subject to change

| | | |
|--------------------------------------------------------------------------------------------------------------------------|--|-------|
| Howerton Building, Room 202 615 Howerton Court Jefferson City, MO 65109 <i>Public attendance may be limited</i> | | Webex |
|--------------------------------------------------------------------------------------------------------------------------|--|-------|

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*